drugset
drugset / Trial / NCT03795909

Ruxolitinib Combined With Dexamethasone for HLH

NCT03795909 ↗

Phase 1/2 Unknown 50 enrolled Capital Research Institute of Pediatrics
RandomizedSequentialSingle-blindTreatment

Summary

A protocol named as "HLH-DR" for patients with refractory and secondary hemophagocytic lymphohistiocytosismay.

Timeline

Start
2017-03-01
Primary completion
2020-03-01
Completion
2022-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule 2.5 mg Oral
Subject Ruxolitinib Small molecule 5 mg Oral
Subject Ruxolitinib Small molecule 10 mg Oral
Background Dexamethasone Small molecule 10 mg/m2 —

Indications

secondary hemophagocytic lymphohistiocytosis